Jeffrey Matous

7.8k total citations · 2 hit papers
128 papers, 4.2k citations indexed

About

Jeffrey Matous is a scholar working on Hematology, Genetics and Pathology and Forensic Medicine. According to data from OpenAlex, Jeffrey Matous has authored 128 papers receiving a total of 4.2k indexed citations (citations by other indexed papers that have themselves been cited), including 63 papers in Hematology, 60 papers in Genetics and 53 papers in Pathology and Forensic Medicine. Recurrent topics in Jeffrey Matous's work include Chronic Lymphocytic Leukemia Research (59 papers), Multiple Myeloma Research and Treatments (55 papers) and Lymphoma Diagnosis and Treatment (52 papers). Jeffrey Matous is often cited by papers focused on Chronic Lymphocytic Leukemia Research (59 papers), Multiple Myeloma Research and Treatments (55 papers) and Lymphoma Diagnosis and Treatment (52 papers). Jeffrey Matous collaborates with scholars based in United States, Canada and France. Jeffrey Matous's co-authors include Ranjana H. Advani, Radhakrishnan Ramchandren, Michelle A. Fanale, Nancy L. Bartlett, Joseph D. Rosenblatt, Pauline Brice, Steven P. Treon, Andrei R. Shustov, Tim Illidge and Joseph M. Connors and has published in prestigious journals such as New England Journal of Medicine, Nature Medicine and Journal of Clinical Oncology.

In The Last Decade

Jeffrey Matous

118 papers receiving 4.1k citations

Hit Papers

Brentuximab Vedotin (SGN-35) in Patients With Relapsed or... 2012 2026 2016 2021 2012 2023 200 400 600
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Systemic Anaplastic Large-Cell Lymphoma: Results of a Phase II Study
    2012 711 citations Ranjana H. Advani, Jeffrey Matous et al. Journal of Clinical Oncology profile →
  2. Allogeneic BCMA-targeting CAR T cells in relapsed/refractory multiple myeloma: phase 1 UNIVERSAL trial interim results
    2023 168 citations Jeffrey Matous, Saurabh Chhabra et al. profile →

Peers

Jeffrey Matous
Comparison fields: 5 of 78
  • Pathology and Forensic Medicine 2.3k
  • Oncology 1.8k
  • Genetics 1.6k
  • Hematology 1.2k
  • Molecular Biology 1.0k
Replace Wojciech Jurczak with:
Wojciech Jurczak Poland
Craig B. Reeder United States
Mathias Rummel Germany
Christiane Pott Germany
Michael Unterhalt Germany
Paul M. Barr United States
Catherine Spier United States
Margaret Macro France
Sergej Konoplev United States
Amanda F. Cashen United States
Wojciech Jurczak Poland View profile →
Citations per field, relative to Jeffrey Matous
Jeffrey Matous · 1×
Citations per year, relative to Jeffrey Matous
Jeffrey Matous · 1×

Countries citing papers authored by Jeffrey Matous

Since Specialization
Citations

This map shows the geographic impact of Jeffrey Matous's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jeffrey Matous with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jeffrey Matous more than expected).

Fields of papers citing papers by Jeffrey Matous

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jeffrey Matous. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jeffrey Matous. The network helps show where Jeffrey Matous may publish in the future.

Co-authorship network of co-authors of Jeffrey Matous

This figure shows the co-authorship network connecting the top 25 collaborators of Jeffrey Matous. A scholar is included among the top collaborators of Jeffrey Matous based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jeffrey Matous. Jeffrey Matous is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
# Work Indexed citations
1
Report of Consensus Panel 3 from the 12th International Workshop on Waldenstrom's Macroglobulinemia on the management of patients with high-risk disease
2025 ·Seminars in Hematology ·Prashant Kapoor, Meletios Α. Dimopoulos, Stephen M. Ansell, Efstathios Kastritis, Ranjana H. Advani, Éric Durot, Pierre Morel, Charalampia Kyriakou, Roman Hájek, Daniela Drandi, Jithma P. Abeykoon, Signy Chow, (unknown), Christopher J. Patterson, Jeffrey Matous, Christian Buske, Steven P. Treon, Marie José Kersten
1
2
Report of Consensus Panel 5 from the 12th International Workshop on Waldenstrom's Macroglobulinemia on the management of patients with intolerance or resistance to covalent BTK inhibitors
2025 ·Seminars in Hematology ·Jorge J. Castillo, Francesco Autore, Neil L. Berinstein, Andrew R. Branagan, Meletios Α. Dimopoulos, Carlos Fernández de Larrea, Simone Ferrero, Prashant Kapoor, Efstathios Kastritis, Jahanzaib Khwaja, Monique C. Minnema, Lugui Qiu, John F. Seymour, Josephine M. I. Vos, Christopher J. Patterson, Christian Buske, Jeffrey Matous, Steven P. Treon, M. Lia Palomba
0
3
Report of Consensus Panel 2 from the 12th International Workshop on the management of Bing-Neel syndrome in patients with Waldenstrom’s Macroglobulinemia
2025 ·Seminars in Hematology ·Shayna Sarosiek, (unknown), Andrew R. Branagan, Simone Ferrero, Jahanzaib Khwaja, Eva Kimby, Damien Roos‐Weil, Naohiro Sekiguchi, Marek Trněný, Shuhua Yi, Christopher J. Patterson, Christian Buske, Jeffrey Matous, Steven P. Treon, Monique C. Minnema
0
4
Report of Consensus Panel 6 from the 12th International Workshop on Waldenstrom's Macroglobulinemia on Diagnosis and Management of Transformed Waldenstrom's Macroglobulinemia
2025 ·Seminars in Hematology ·Éric Durot, Jithma P. Abeykoon, Damien Roos‐Weil, (unknown), Charalampia Kyriakou, David F. Moreno, Stephen M. Ansell, Rebecca Auer, Xinxin Cao, Roger G. Owen, Shuhua Yi, Irene Dogliotti, Marek Trněný, Christopher J. Patterson, Jeffrey Matous, Christian Buske, Steven P. Treon, Ranjana H. Advani
1
5
Phase II Study of Isatuximab, and Weekly Carfilzomib + Dexamethasone in Relapsed and Refractory Multiple Myeloma (RRMM)
2024 ·Blood ·David H. Vesole, Thomas G Martin, Suzanne Trudel, (unknown), (unknown), Noa Biran, Jeffrey L. Wolf, Jeffrey Matous, Pamela N. Münster, (unknown), Jesús G. Berdeja
1
6
Updated efficacy and safety results of BCL-2 inhibitor lisaftoclax (APG-2575) alone or combined with ibrutinib or rituximab in patients (pts) with Waldenström macroglobulinemia (WM).
2024 ·Journal of Clinical Oncology ·Masa Lasica, Sikander Ailawadhi, Chengcheng Fu, Sheeba K. Thomas, Depei Wu, Shuhua Yi, Tanya Siddiqi, Qingsong Yin, John N. Allan, Wen-Ming Chen, Jeffrey Matous, Ru Feng, Zi Chen, Min Yu, Mingyu Li, (unknown), (unknown), Hengbang Wang, Asher Chanan‐Khan, Yifan Zhai
1
7
Pomalidomide/Daratumumab/Dexamethasone in Relapsed or Refractory Multiple Myeloma: Final Overall Survival From MM-014
2024 ·Clinical Lymphoma Myeloma & Leukemia ·Nizar J. Bahlis, Christy Samaras, Donna Reece, Michaël Sébag, Jeffrey Matous, Jesús G. Berdeja, Jesse Shustik, Gary J. Schiller, Siddhartha Ganguly, Kevin Song, Christopher S. Seet, Mirelis Acosta-Rivera, Michael Bär, Donald P. Quick, Gustavo Fonseca, Hongjuan Liu, Christian Gentili, (unknown), David S. Siegel
2
8
MM-344 Longer-Term Follow-up of Patients Receiving Prophylactic Tocilizumab for the Reduction of Cytokine Release Syndrome (CRS) in the Phase 1/2 MajesTEC-1 Study of Teclistamab in Relapsed/Refractory Multiple Myeloma (RRMM)
2024 ·Clinical Lymphoma Myeloma & Leukemia ·(unknown), Alfred L. Garfall, Lotfi Benboubker, Katarina Uttervall, (unknown), Laura Rosiñol, Jeffrey Matous, Deeksha Vishwamitra, Caroline Hodin, Tara Stephenson, Keqin Qi, Athena F. Zuppa, Katherine Chastain, María-Victoria Mateos
1
9
MM-371 Pomalidomide, Daratumumab, and Dexamethasone After Lenalidomide Treatment in Patients With Relapsed or Refractory Multiple Myeloma (RRMM): Final Overall Survival (OS) Analysis of the Phase II MM-014 Study
2023 ·Clinical Lymphoma Myeloma & Leukemia ·Nizar J. Bahlis, Christy Samaras, Donna Reece, Michaël Sébag, Jeffrey Matous, Jesús G. Berdeja, Jesse Shustik, Gary J. Schiller, Siddhartha Ganguly, Kevin Song, Christopher S. Seet, Mirelis Acosta-Rivera, Donald P. Quick, Bertrand Anz, Gustavo Fonseca, Hongjuan Liu, Christian Gentili, David S. Siegel
1
10
P882: POMALIDOMIDE, DARATUMUMAB, AND DEXAMETHASONE AFTER LENALIDOMIDE TREATMENT IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): FINAL OVERALL SURVIVAL ANALYSIS OF THE PHASE 2 MM-014 STUDY
2023 ·HemaSphere ·Nizar J. Bahlis, Christy Samaras, Donna Reece, Michaël Sébag, Jeffrey Matous, Jesús G. Berdeja, Jesse Shustik, Gary J. Schiller, Siddhartha Ganguly, Kevin Song, Christopher S. Seet, Mirelis Acosta-Rivera, Donald P. Quick, Bertrand Anz, Gustavo Fonseca, (unknown), Hongjuan Liu, Christian Gentili, David S. Siegel
1
11
P902: ISATUXIMAB, WEEKLY CARFILZOMIB AND DEXAMETHASONE AS SALVAGE THERAPY FOR RRMM; INTERIM RESULTS FROM A PHASE 2 TRIAL.
2023 ·HemaSphere ·David H. Vesole, Jesús G. Berdeja, Jeffrey Matous, Suzanne Trudel, (unknown), Pamela N. Münster, (unknown), Benjamin Sun, Tom Martin
0
12
Single-Agent Ibrutinib for Rituximab-Refractory Waldenström Macroglobulinemia: Final Analysis of the Substudy of the Phase III InnovateTM Trial
2021 ·Clinical Cancer Research ·Judith Trotman, Christian Buske, Alessandra Tedeschi, Jeffrey Matous, D. Blair Macdonald, Constantine S. Tam, Olivier Tournilhac, Shuo Ma, Steven P. Treon, Albert Oriol, Jerry Ping, Eva M. Briso, Israel Arango‐Hisijara, Meletios Α. Dimopoulos
27
13
Non-Myeloablative Hematopoietic Stem Cell Transplantation (NMA HSCT) Utilizing Low-Dose Total Body Irradiation (TBI) Plus Fludarabine (Flu): A Comparison of Single-Center Based Flu 150 mg/m2 Plus 400 Cgy TBI Versus Flu 90 mg/m2 and 200 Cgy TBI Containing Regimens
2021 ·Transplantation and Cellular Therapy ·(unknown), Richard A. Nash, Ted Gooley, Tara Gregory, Jeffrey Matous, Luke Mountjoy, Julie A. Murphy, Marcello Rotta, (unknown), Michael Tees, Peter A. McSweeney, Michael Maris
0
14
A phase I/II study of the combination of panobinostat and carfilzomib in patients with relapsed or relapsed/refractory multiple myeloma: Final analysis of second dose‐expansion cohort
2021 ·American Journal of Hematology ·Jesús G. Berdeja, Tara Gregory, Edward A. Faber, Lowell L. Hart, Joseph R. Mace, Edward Arrowsmith, Ian W. Flinn, Jeffrey Matous
13
15
Combination trial of duvelisib (IPI‐145) with rituximab or bendamustine/rituximab in patients with non‐Hodgkin lymphoma or chronic lymphocytic leukemia
2019 ·American Journal of Hematology ·Ian W. Flinn, Mohamad Cherry, Michael B. Maris, Jeffrey Matous, Jesús G. Berdeja, Manish R. Patel
33
16
Population pharmacokinetics of pomalidomide in patients with relapsed or refractory multiple myeloma with various degrees of impaired renal function
2017 ·Clinical Pharmacology Advances and Applications ·Yan Li, Xiaomin Wang, Edward O’Mara, Meletios Α. Dimopoulos, Pieter Sonneveld, Katja Weisel, Jeffrey Matous, David S. Siegel, Jatin J. Shah, (unknown), Lars Sternås, (unknown), Mohamed H. Zaki, Maria Palmisano, Simon Zhou
10
17
Initial Phase 2 Results of Ibrutinib Combined with Carfilzomib/Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma
2017 ·Blood ·Ajai Chari, Saulius Girnius, Saurabh Chhabra, Robert F. Cornell, Cristina Gasparetto, Chatchada Karanes, Matthew A. Lunning, Jeffrey Matous, Rubén Niesvizky, Chaim Shustik, Robert K. Stuart, (unknown), (unknown), Zeena Salman, Thorsten Graef, Jason Valent
2
18
Brentuximab Vedotin Plus Bendamustine: A Highly Active Salvage Treatment Regimen for Patients with Relapsed or Refractory Hodgkin Lymphoma
2015 ·Blood ·Ann S. LaCasce, Gregory Bociek, Ahmed Sawas, Paolo F. Caimi, Edward Agura, Jeffrey Matous, Stephen M. Ansell, Howland E. Crosswell, Miguel Islas‐Ohlmayer, Caroline Behler, Eric Cheung, Andres Forero‐Torres, Julie M. Vose, Owen A. O’Connor, Neil C. Josephson, Ranjana H. Advani
43
19
Brentuximab Vedotin in Combination with Bendamustine for Patients with Hodgkin Lymphoma who are Relapsed or Refractory after Frontline Therapy
2014 ·Blood ·Ann S. LaCasce, R. Gregory Bociek, Jeffrey Matous, Ahmed Sawas, Paolo Caimi, Stephen M. Ansell, Miguel Islas‐Ohlmayer, Eric Cheung, Edward Agura, Caroline Behler, Howland E. Crosswell, Julie M. Vose, Neil C. Josephson, Ranjana H. Advani
20
20
Control of Plasma Uric Acid in Adults at Risk for Tumor Lysis Syndrome: Efficacy and Safety of Rasburicase Alone and Rasburicase Followed by Allopurinol Compared With Allopurinol Alone—Results of a Multicenter Phase III Study
2010 ·Journal of Clinical Oncology ·Jörge E. Cortes, Joseph O. Moore, Richard T. Maziarz, Meir Wetzler, Michael Craig, Jeffrey Matous, Selina M. Luger, Bimalangshu R. Dey, Gary J. Schiller, Dat C. Pham, Camille N. Abboud, (unknown), (unknown), Abderrahmane Laadem, Karen Seiter
127

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Wojciech Jurczak Breakdown of academic impact, for papers by Craig B. Reeder Breakdown of academic impact, for papers by Mathias Rummel Breakdown of academic impact, for papers by Christiane Pott Breakdown of academic impact, for papers by Michael Unterhalt Breakdown of academic impact, for papers by Paul M. Barr Breakdown of academic impact, for papers by Catherine Spier Breakdown of academic impact, for papers by Margaret Macro Breakdown of academic impact, for papers by Sergej Konoplev Breakdown of academic impact, for papers by Amanda F. Cashen
Rankless by CCL
2026